4.6 Article

Dendritic cells mediate NK cell help for Th1 and CTL responses: Two-signal requirement for the induction of NK cell helper function

Journal

JOURNAL OF IMMUNOLOGY
Volume 171, Issue 5, Pages 2366-2373

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.171.5.2366

Keywords

-

Categories

Funding

  1. NCI NIH HHS [CA 80216] Funding Source: Medline
  2. NIAID NIH HHS [R01 AI152655] Funding Source: Medline

Ask authors/readers for more resources

Early stages of viral infections are associated with local recruitment and activation of dendritic cells (DC) and NK cells. Although activated DC and NK cells are known to support each other's functions, it is less clear whether their local interaction in infected tissues can modulate the subsequent ability of migrating DC to induce T cell responses in draining lymph nodes. In this study, we report that NK cells are capable of inducing stable type 1-polarized effector/memory DC (DC1) that act as carriers of NK cell-derived helper signals for the development of type 1 immune responses. NK cell-induced DC1 show a strongly elevated ability to produce IL-12p70 after subsequent CD40 ligand stimulation. NK-induced DC1 prime naive CD4(+) Th cells for high levels of IFN-gamma, but low IL-4 production, and demonstrate a strongly enhanced ability to induce Ag-specific CD8(+) T cell responses. Resting NK cells display stringent activation requirements to perform this novel, DC-mediated, helper function. Although their interaction with K562 cells results in effective target cell killing, the induction of DO requires a second NK cell-activating signal. Such costimulatory signal can be provided by type I IFNs, common mediators of antiviral responses. Therefore, in addition to their cytolytic function, NK cells also have immunoregulatory activity, induced under more stringent conditions. The currently demonstrated helper activity of NK cells may support the development of Th1- and CTL-dominated type 1 immunity against intracellular pathogens and may have implications for cancer immunotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available